Oxford Nanopore at AGBT 2026 General Meeting
)
Overview
Oxford Nanopore will be at the AGBT General Meeting in February, 2026, hosted in Orlando. Stop by the Lake Room in the Sponsor promenade, and join our evening activities. See additional details below.
Sponsor Workshop
A new era of biological discovery
Date: Wednesday, February 25
Time: 3:35 - 3:50 PM EST
Location: Floridian Ballroom
Agenda
3:35 PM- 3:50 PM ET | Talk title | Speaker |
|---|---|---|
3:35 PM - 3:40 PM | A new era of biological discovery | Lakmal Jayasinghe, Oxford Nanopore Technologies |
3:40 PM - 3:50 PM | Translational and clinical applications of long-read sequencing technologies in oncology | Marilyn Li, The Children's Hospital of Philadelphia, Univ. Pennsylvania Perelman School of Medicine |
Workshop speakers
)
Lakmal Jayasinghe, Chief Scientific Officer, Oxford Nanopore TechnologiesDr Lakmal Jayasinghe is the Chief Scientific Officer at Oxford Nanopore Technologies, where he leads the company's scientific vision, driving groundbreaking research and development to advance innovation in nanopore sequencing and its transformative applications.
Before joining Oxford Nanopore in 2006, Dr Jayasinghe completed his PhD in chemical biology at the University of Oxford, where he was a member of the Hagan Bayley group. His research focused on the study and engineering of nanopores using genetic and chemical approaches, providing him with a deep understanding of nanopore technology. During his tenure at Oxford Nanopore, the company has achieved unprecedented advancements in sequencing accuracy, throughput, and versatility, enabling global researchers to explore applications spanning genomics, transcriptomics, and epigenetics. Lakmal has also championed advancements in direct RNA sequencing, revolutionising the study of native RNA molecules and their modifications, both in academic research and the biopharma industry. Over his time with Oxford Nanopore, Lakmal has held several leadership positions, including Senior Scientist, Principal Scientist, and Vice President, where he has led interdisciplinary R&D teams in biologics.
Dr Jayasinghe actively collaborates with worldwide academic partners to ensure that Oxford Nanopore leverages the best biological components and chemistries in its platforms. He actively supports initiatives in education, skill development, and partnerships aimed at democratising access to sequencing technology. A strong advocate for multi-omics approaches, Lakmal envisions a future where Oxford Nanopore’s technology seamlessly integrates genomics, transcriptomics, proteomics, and metabolomics to tackle complex biological questions and improve human health.
Nanopore sequencing has emerged as a transformative long-read technology with rapidly expanding translational and clinical applications in oncology. By enabling real-time sequencing of native DNA and RNA molecules, nanopore platforms uniquely provide long-range genomic information while simultaneously detecting epigenetic modifications, including DNA methylation, without chemical conversion. These capabilities address critical limitations of short-read sequencing and are particularly well suited to the complex genomic and epigenomic landscapes that characterize cancer.
Nanopore sequencing has emerged as a transformative long-read technology with rapidly expanding translational and clinical applications in oncology. By enabling real-time sequencing of native DNA and RNA molecules, nanopore platforms uniquely provide long-range genomic information while simultaneously detecting epigenetic modifications, including DNA methylation, without chemical conversion. These capabilities address critical limitations of short-read sequencing and are particularly well suited to the complex genomic and epigenomic landscapes that characterize cancer.
)
Marilyn Li, Professor of Pathology and Pediatrics, Vice Chief of Division of Genomic Diagnostics, Director of Cancer Genomic Diagnostics, The Children's Hospital of Philadelphi & Univ. Pennsylvania Perelman School of Medicine
Workshop speakers
Rapid genomic diagnosis in critically ill patients remains a clinical imperative, particularly when standard testing timelines exceed actionable windows. Here, we implemented an ultrarapid long-read nanopore sequencing (urLR-NS) workflow for critically ill intensive care patients, integrating single-nucleotide, structural variation, mitochondrial, and methylation analyses within a unified pipeline. Mean time from sample to interpreted result was 5.3 days, significantly shorter than contemporaneous short-read clinical genomic care (mean 18.4 days in our center), enabling more timely clinical decisions. Pathogenic variants were identified in 42% of cases (11/26), with direct clinical impact in 64% of diagnosed patients (7/11) via altered management, tailored therapy, or targeted surveillance strategies.
Rapid genomic diagnosis in critically ill patients remains a clinical imperative, particularly when standard testing timelines exceed actionable windows. Here, we implemented an ultrarapid long-read nanopore sequencing (urLR-NS) workflow for critically ill intensive care patients, integrating single-nucleotide, structural variation, mitochondrial, and methylation analyses within a unified pipeline. Mean time from sample to interpreted result was 5.3 days, significantly shorter than contemporaneous short-read clinical genomic care (mean 18.4 days in our center), enabling more timely clinical decisions. Pathogenic variants were identified in 42% of cases (11/26), with direct clinical impact in 64% of diagnosed patients (7/11) via altered management, tailored therapy, or targeted surveillance strategies.
)
Mark Drost, Clinical Laboratory Geneticist, Erasmus MC
